We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Medical

PHARMASEAL

Status: Extended

Sep 21st 2020 - Nov 10th 2020

Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

read more read less

PHARMASEAL Rating Review

Pitch rating powered by CROWDRATING

Rated on 01/10/2020

Pitch Rated

78%

overall

Management

87%

Product

77%

Investment

69%

Log in to view amount pledged

    Log in to view target

    £1,045,120
    pre-money valuation

    32.36%
    equity available

    588
    investors

    £905
    pledge per investor

    09993255
    company number

    Active
    company status

    08/02/2016
    incorporated 8 years

    Previous Funding rounds
    23 Apr 24 Seedrs £532,311 / 106% 77.67%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 87%

Skills 91%
PHARMASEAL's management team is led by the Founder/CEO who is an expert in enterprise architecture, requirement analysis, software development life cycle, clinical development, agile methodologies, software project management and strategic IT management. The Director of Product Management is specialising in the understanding of customer requirements and developed products that are valuable, innovative and successful, supporting pharmacovigilance and clinical operations. He has also published various publications including Clinical Trial Technology. The Business Development Director is well versed in data management, CRO management, clinical research, business development, budget monitoring and project management. The Director of Quality & Operations is a PhD Scientist with specialities in drug development, standard operating procedure, quality assurance, regulatory submissions, clinical trial management and preclinical studies. The Director of the company is skilled in business strategy, business process improvement, change management, business analysis and accounting. It was also noted that they have not yet appointed a dedicated finance head in the team.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £1,045,120
    pre-money valuation

    32.36%
    equity available

    588
    investors

    £905
    pledge per investor

    09993255
    company number

    Active
    company status

    08/02/2016
    incorporated 8 years

    Previous Funding rounds
    23 Apr 24 Seedrs £532,311 / 106% 77.67%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph